18-ICML Posters will be available in two formats:
- ON-SITE - in the Poster Area (printed format);
- ONLINE - in the E-Poster Gallery (PDF format).
1. ON-SITE POSTER AREA
Where: Marquee Parco Ciani, connected to Palazzo dei Congressi by a covered path;
When: Wednesday, 18 (12:00-18:00), Thursday, 19 (10:00-18:00) and Friday, 20 June (10:00-17:00*).
Posters will be on display throughout the conference. Presenters are kindly asked to be available by their poster for Q&A with attendees from 12:30 to 13:00, as scheduled below:
-
Thursday, 19 June: odd-numbered posters
-
Friday, 20 June: even-numbered posters
Posters may be removed on Friday, 20 June from 17:15 to 17:45*.
Conference staff will remove all posters left on the boards after 17:45*.
18-ICML does not bear any responsibility for returning uncollected material to authors.
*Schedule revised for security reasons (Exhibition Area dismantling).
2. E-POSTER GALLERY
Accessible to 18-ICML attendees as of Wednesday, 18 June from 8:30 CEST to Friday, 12 December 23:59 CET.
Lymphoma biology
| 168 | Zi Yan Charmaine Ong | C5ORF30/ MACIR is a robust prognostic marker in DLBCL, and modulates the tumor microenvironment through HLA expression | Lymphoma biology |
| 169 | Aitana Avendaño Pomares | Phospho-STAT3 Expression and JAK/STAT Pathway Activation across Genetic Subtypes of Diffuse Large B-Cell Lymphoma | Lymphoma biology |
| 170 | Karan L Chohan | Role of Non-Coding RNAs and DNA Methylation in Regulating Intracellular Signaling and Cytokine Pathways in MYD88WT Waldenström Macroglobulinemia: A Multi-Omic Analysis | Lymphoma biology |
| 171 | Baizhi Chen | Stabilized MYCT58A Bypasses T-Cell Help to Fuel Germinal Center B-Cell Lymphomagenesis | Lymphoma biology |
| 172 | Allison Chan | Aggressive B-cell lymphomas retain ATR-dependent determinants of T-cell exclusion from the Germinal Center Dark Zone | Lymphoma biology |
| 173 | Giulio Sartori | FLI1 Interactome in Diffuse Large B-Cell Lymphoma Identifies ATG9A as a Novel Autophagy-Related Interactor | Lymphoma biology |
| 174 | Ondrej Havranek | Phosphoinositide dependent protein kinase 1 is a key metabolic regulator and potential therapeutic target in lymphoma. | Lymphoma biology |
| 175 | Thomas Witzig | Cyclin D1 Overexpression Induces Replication Stress and Microhomology-Mediated End-Joining Dependence for DNA Damage Repair in Mantle Cell Lymphoma |
Lymphoma biology |
Lymphoma genetics
| 176 | Huayuan Zhu | EGR2 mutations Confer Poor Prognosis in Chronic Lymphocytic Leukemia Treated with Bruton Tyrosine Kinase Inhibitors | Lymphoma genetics |
| 177 | Ramón Diez-Feijóo | Genetic Profiling of Marginal Zone Lymphoma in ctDNA at Diagnosis and During Follow-up: Diagnostic and Prognostic Implications | Lymphoma genetics |
| 178 | Weili Zhao | Clinical characteristics and molecular heterogeneity in Follicular Lymphoma with extranodal involvement | Lymphoma genetics |
| 179 | Miguel Canales | Genomic and transcriptional single-cell heterogeneity in germinal-center (GC) lymphomas: insights into follicular lymphoma transformation | Lymphoma genetics |
| 180 | Daniel J Landsburg | Impact of TP53 mutations and copy number loss on survival outcomes for patients with newly diagnosed large B cell lymphomas | Lymphoma genetics |
| 181 | Mariana Bastos-Oreiro | MYC rearrangements in large B-cell lymphomas: impact of the breakpoint and partner on prognosis | Lymphoma genetics |
| 182 | Rita Tavarozzi | Genomic testing in patients with large cell and follicular lymphoma treated with T-cell engagers bi-specific antibodies and correlation with treatment response | Lymphoma genetics |
| 183 | Alfredo Rivas-Delgado | Mutational Landscape of B-Cell Lymphomas: Clinical Evaluation of the MSK-ACCESS Heme cell-free DNA Next-Generation Sequencing Assay | Lymphoma genetics |
| 184 | Yanwen Jiang | Genomic profiling of extranodal (EN) disease in patients (pts) with diffuse large B-cell lymphoma(DLBCL): A combined analysis of POLARIX and GOYA | Lymphoma genetics |
| 185 | Manik Uppal | Comprehensive analysis identifies distinct patterns of molecular alterations across age groups in diffuse large B-cell lymphoma | Lymphoma genetics |
| 186 | Svenja Höfmann | An In Vivo PiggyBac Insertional Mutagenesis Screen To Search for Modifiers of Myd88L265P-driven DLBCL Lymphomagenesis | Lymphoma genetics |
| 187 | Jonathan H Schatz | Mutational BCL10 Activation Cooperates with BCL6 in DLBCL Lymphomagenesis Facilitating Subtype-Specific Precision In Vivo Modeling | Lymphoma genetics |
| 188 | Marc Bosch Schips | Influence of TP53 gene alterations in patients with Relapsed/Refractory (R/R) Large B-cell Lymphoma (LBCL) treated with Bispecific Antibodies (BsAbs) | Lymphoma genetics |
| 189 | James Louis Rubenstein | Therapy-Driven Evolution and Intratumoral Genetic Heterogeneity in CNS Lymphomas | Lymphoma genetics |
| 190 | Bauke Ylstra | Oncogenesis of Enteropathy-Associated T-cell lymphoma: extensive parallel clonal evolution and its clinical consequences | Lymphoma genetics |
Lymphoma classification
| 191 | Karin Ekström Smedby | InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO 5th Edition classification (2024) | Lymphoma classification |
| 192 | Allison Barraclough | Follicular lymphoma displays distinct gene expression profiles according to histological grade | Lymphoma classification |
| 193 | Weicheng Ren | Whole-genome sequencing reveals three follicular lymphoma subtypes with distinct cell-of-origin and patient outcomes | Lymphoma classification |
| 194 | Christopher Oakes | A novel approach for classification of splenic B cell lymphoma using DNA methylation reveals diverse biological disease mechanisms | Lymphoma classification |
| 195 | Wei Xu | Multi-omics dissection of EBV-driven heterogeneity, metabolic remodeling, and tumor cellular landscape in ENKTL progression | Lymphoma classification |
| 196 | Ng Siok Bian | DNA Methylation Signatures Distinguish Extranodal NK/T-cell Lymphoma (ENKTL) and EBV-Positive Nodal T/NK-Cell Lymphoma (nTNKL) and Identify Prognostic Subgroups | Lymphoma classification |
Lymphoma microenvironment
| 197 | Thiago M. Steiner | CD4+ T cell recruitment and differentiation into a cytotoxic phenotype is associated with the treatment of patients with glofitamab together with R-CHOP or Pola-R-CHP | Lymphoma microenvironment |
| 198 | Edith Szafer-Glusman | CD3xCD20 bispecific epcoritamab induces antitumor activity and favorable T-cell dynamics over time with prolonged therapy | Lymphoma microenvironment |
| 199 | Zhi-Zhang Yang | Pembrolizumab therapy induces an inflammatory response in lymphoma patients by reshaping monocytes resulting in hyperprogressive disease | Lymphoma microenvironment |
| 200 | Alan Zhou | Spatial Transcriptomics Reveals Immune Microenvironment Remodeling in Cutaneous T-Cell Lymphoma Post-Radiation and Biomarkers of Disease Progression | Lymphoma microenvironment |
| 201 | Monika Szelest | Gut microbiome-derived short-chain fatty acid sodium butyrate shape the immune response in chronic lymphocytic leukemia | Lymphoma microenvironment |
| 202 | LINGLING ZHANG | Immunosurveillance of Precancerous Germinal Center B Cells | Lymphoma microenvironment |
| 203 | Andrea Rivero | Characterization and clinical impact of the circulating immune cell profile in patients with follicular lymphoma (FL) | Lymphoma microenvironment |
| 204 | Shruti Sridhar | An explainable artificial intelligence mDELRelapseNet model to predict relapse in Diffuse Large B-Cell Lymphoma based on the Spatial Organization of MYC+BCL2+BCL6- Cells | Lymphoma microenvironment |
| 205 | Emma Pettersson | Investigating Neutrophil Extracellular Traps as a possible prognostic marker in diffuse large B-cell lymphoma and classical Hodgkin lymphoma | Lymphoma microenvironment |
| 206 | Anand D. Jeyasekharan | Spatial and Single-Cell Multi-omics Reveal Macrophage Heterogeneity between Primary CNS Lymphoma (PCNSL) and Diffuse Large B-Cell Lymphoma (DLBCL) | Lymphoma microenvironment |
| 207 | Izidore S. Lossos | Association between Nodular lymphocyte-predominant Hodgkin Lymphoma and Moraxella catarrhalis | Lymphoma microenvironment |
Chronic lymphocytic leukemia
| 208 | Alexey Danilov | Comparative efficacy of ibrutinib vs other covalent Bruton tyrosine kinase inhibitors in first-line chronic lymphocytic leukemia: A matched-adjusted indirect comparison | Chronic lymphocytic leukemia |
| 209 | Talha Munir | Efficacy of continuous zanubrutinib vs fixed-duration venetoclax in combination with obinutuzumab in treatment-naive CLL: a matching-adjusted indirect comparison | Chronic lymphocytic leukemia |
| 210 | Ryan Jacobs | Real-world comparative effectiveness of first-line Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia | Chronic lymphocytic leukemia |
| 211 | Matthew S. Davids | Preliminary results of the ongoing multicenter, phase 2 study of retreatment with venetoclax plus obinutuzumab (ReVenG) in patients with recurrent CLL | Chronic lymphocytic leukemia |
| 212 | Jennifer L. Crombie | SAVE (Safe Accelerated Venetoclax Escalation): Results of a prospective, phase Ib study of venetoclax with an accelerated dose ramp-up in patients with CLL | Chronic lymphocytic leukemia |
| 213 | Mazyar Shadman | Combination of zanubrutinib + venetoclax for treatment-naive CLL/SLL: results in SEQUOIA arm D | Chronic lymphocytic leukemia |
| 214 | Mazyar Shadman | Final Independent Review Data Supports Sustained Benefit of Zanubrutinib over Ibrutinib in Patients with R/R CLL/SLL in ALPINE | Chronic lymphocytic leukemia |
| 215 | Ana Carla De Oliveira | Discontinuation of BTK Inhibitor Monotherapy in CLL Patients Without Disease Progression: A Real-World (RW) Study from the Spanish CLL Group (GELLC) | Chronic lymphocytic leukemia |
| 216 | Bita Fakhri | EPCORITAMAB MONOTHERAPY IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLINICAL AND TRANSLATIONAL RESULTS FROM EPCORE CLL-1 | Chronic lymphocytic leukemia |
| 217 | Andreas Katsimigas | Richter's transformed chronic lymphocytic leukemia of diffuse large B-cell lymphoma (DLBCL) - type compared to de novo DLBCL in a nationwide cohort | Chronic lymphocytic leukemia |
| 218 | John F. Seymour | Analysis of COVID-19 Infections With Fixed-Duration Acalabrutinib-Venetoclax Combinations in Treatment-Naive Chronic Lymphocytic Leukemia in the Phase 3 AMPLIFY Trial | Chronic lymphocytic leukemia |
| 219 | Paul Barr | Patient reported outcomes from BRUIN CLL-321: Phase 3 trial comparing pirtobrutinib to idelalisib/rituximab or bendamustine/rituximab in covalent BTKi pretreated CLL/SLL | Chronic lymphocytic leukemia |
| 220 | Enrico Tiacci | HIGH EFFICACY OF BRIEF BRAF AND MEK COINHIBITION, ALONE AND COMBINED WITH ANTI-CD20 IMMUNOTHERAPY, IN RELAPSED/REFRACTORY (R/R) HAIRY CELL LEUKEMIA (HCL): A PHASE-2 TRIAL | Chronic lymphocytic leukemia |
Follicular Lymphoma
| 221 | Eliza A Hawkes | Determining the prognostic significance of the Ki67 proliferation index in treatment-naïve follicular lymphoma: An Australasian Lymphoma Registry (LaRDR) study | Follicular Lymphoma |
| 222 | Kennosuke Karube | Exploration of surrogate markers for EZH2 Y646 mutation in follicular lymphoma: comparative study including matched pair samples | Follicular Lymphoma |
| 223 | Rexhep Durmo | Prognostic Role of interim ΔSUVmax in Follicular Lymphoma | Follicular Lymphoma |
| 224 | George Cholack | Regular Aspirin Use Prior to Diagnosis and Follicular Lymphoma Prognosis: Novel Association with Superior Event-Free Survival | Follicular Lymphoma |
| 225 | Wataru Munakata | The FOREST Study: A Prospective Observational Study on Real-World Management and Outcomes of Follicular Lymphoma in Japan | Follicular Lymphoma |
| 226 | Dor Shpitzer | Follicular Lymphoma Transformation: Real-World Analysis including effect of rituximab/obinutuzumab | Follicular Lymphoma |
| 227 | Reid Merryman | Rituximab and Epcoritamab as First-line Therapy for Patients with High-tumor Burden Follicular Lymphoma: First Results of a Multicenter Phase II Trial | Follicular Lymphoma |
| 228 | Aneeqa Zafar | A UC Hematologic Malignancy Consortium Phase II Trial of Obinutuzumab, Ibrutinib and Venetoclax in Patients with Previously Untreated Follicular Lymphoma | Follicular Lymphoma |
| 229 | Toby A. Eyre | Safety and efficacy of mosunetuzumab subcutaneous maintenance following mosunetuzumab plus lenalidomide induction therapy in previously untreated follicular lymphoma | Follicular Lymphoma |
| 230 | Eliza A Hawkes | Treatment Of newly-diagnosed Follicular Lymphoma with Rituximab, Golcadomide +/- Nivolumab- Interim analysis of the Phase II TOP-FLOR study | Follicular Lymphoma |
| 231 | Dai Maruyama | Impact of Rituximab Early Administration on Outcomes in Advanced Stage Low Tumor Burden Follicular Lymphoma: Subgroup Analysis of Phase III JCOG1411/FLORA Study | Follicular Lymphoma |
| 232 | Christian Christian Schmidt | Combination of the Intravenous PI3K Inhibitor Copanlisib in Combination with Obinutuzumab in Patients with Previously Untreated Follicular Lymphoma and High Tumor Burden | Follicular Lymphoma |
| 233 | Paul M Barr | S1608: Randomized phase II trial comparing lenalidomide/obinutuzumab and umbralisib/obinutuzumab with chemoimmunotherapy in early progressing follicular lymphoma (POD24) | Follicular Lymphoma |
| 234 | Laurie H. Sehn | Post Hoc Analysis of Outcomes by POD24 Status From the inMIND Study of Tafasitamab Plus Lenalidomide and Rituximab in Relapsed or Refractory Follicular Lymphoma | Follicular Lymphoma |
| 235 | Wojciech Jurczak | Nemtabrutinib in Relapsed or Refractory Follicular Lymphoma: Updated Results From Cohort G of the Phase 2 BELLWAVE-003 Study | Follicular Lymphoma |
| 236 | Chan Y. Cheah | Mosunetuzumab (Mosun) demonstrates durable clinical benefit in patients (pts) with complete response (CR) and high-risk relapsed/refractory (R/R) follicular lymphoma (FL) | Follicular Lymphoma |
| 237 | Laurie H. Sehn | Fixed-duration subcutaneous mosunetuzumab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) with high-risk features: pivotal Phase II study update | Follicular Lymphoma |
| 238 | Lorenzo Falchi | Epcoritamab Plus Lenalidomide and Rituximab Achieves High Response Rates and Survival Benefits Compared With Usual Care in Relapsed/Refractory Follicular Lymphoma | Follicular Lymphoma |
| 239 | Habib Hamidi | Machine Learning Based Unsupervised Multimodal Analysis Identifies Patient Subsets Associated with Response to Mosunetuzumab in Relapsed/Refractory NHL | Follicular Lymphoma |
| 240 | Kim M. Linton | EPCORITAMAB MONOTHERAPY DEMONSTRATES DEEP AND DURABLE RESPONSES AT 3-YEAR FOLLOW-UP IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA | Follicular Lymphoma |
| 241 | Julie M Vose | Matching-Adjusted Indirect Comparison of Epcoritamab With Rituximab + Lenalidomide vs Tafasitamab With Rituximab + Lenalidomide in Second-Line + Follicular Lymphoma | Follicular Lymphoma |
| 242 | Stefano Luminari | Long-term efficacy and survival outcomes with odronextamab in relapsed/refractory follicular lymphoma (R/R FL): 2-year follow-up from the Phase 2 ELM-2 study | Follicular Lymphoma |
| 243 | Alexey Danilov | Real-World Outcomes of CD20xCD3 Bispecific Antibody Therapy in Adult Patients with Relapsed/Refractory Transformed Indolent Lymphoma. | Follicular Lymphoma |
| 244 | Catherine Thieblemont | Tisagenlecleucel Versus Mosunetuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL): A Matching-Adjusted Indirect Comparison (MAIC) Using 3-Year Follow-up Data | Follicular Lymphoma |
| 245 | Loic Ysebaert | Efficacy and Tolerance of CAR T-cells in Patients with Relapsed or Refractory Follicular Lymphoma: Analysis from the French DESCAR-T Registry | Follicular Lymphoma |
| 246 | Loretta J. Nastoupil | Comparative outcomes of lisocabtagene maraleucel (liso-cel) versus an external control arm (ECA) in third-line or later (3L+) R/R follicular lymphoma (FL) |
Follicular Lymphoma |
| 247 | Saurabh Dahiya | Matching-adjusted indirect comparison of lisocabtagene maraleucel versus epcoritamab in patients with third-line or later relapsed or refractory follicular lymphoma |
Follicular Lymphoma |
| 248 | J.C. Villasboas | Matching-Adjusted Indirect Comparison of Epcoritamab With Rituximab + Lenalidomide vs Lisocabtagene Maraleucel in Second-Line Follicular Lymphoma | Follicular Lymphoma |
| 249 | Yassine Al Tabaa | FAST Score : A Machine Learning-Based Model Predicting Early Relapse after CAR T-cells in Follicular Lymphoma. Results from the French DESCAR-T Registry | Follicular Lymphoma |
| 250 | Alfredo Rivas-Delgado | Histological Characteristics, Treatment Patterns, and Outcomes Following Disease Progression After CAR-T Therapy in Relapsed/Refractory Follicular Lymphoma | Follicular Lymphoma |
| 251 | Adam J Olszewski | High Complete Response Rates and Differential Toxicity of Mosunetuzumab and Lenalidomide in Previously Untreated Follicular (FL) and Marginal Zone Lymphoma (MZL) | Follicular Lymphoma |
Marginal zone and lymphoplasmacytic lymphoma
| 252 | Luca Arcaini | IGHV and TP53 mutational status at diagnosis may have impact on outcome in patients with Splenic Marginal Zone Lymphoma | Marginal zone and lymphoplasmacytic lymphoma |
| 253 | Leticia Quintanilla-Martinez | Nodal marginal zone lymphoma: mutational analysis, gene expression profile, and differential diagnosis from other small B-cell lymphomas. | Marginal zone and lymphoplasmacytic lymphoma |
| 254 | Catherine Thieblemont | Rituximab and ibrutinib combination in untreated SMZL and NMZL: Long-term outcome and the impact of early minimal residual disease from the IELSG47/MALIBU Phase II Study | Marginal zone and lymphoplasmacytic lymphoma |
| 255 | Jiadai Xu | The efficacy, safety and rationality of Orelabrutinib plus Obinutuzumab (O2) in systemic treatment-naïve marginal zone lymphoma: a prospective cohort study | Marginal zone and lymphoplasmacytic lymphoma |
| 256 | Alessandra Tucci | Nemtabrutinib in Relapsed or Refractory Marginal Zone Lymphoma: Updated Results From Cohort F of the Phase 2 BELLWAVE-003 Study | Marginal zone and lymphoplasmacytic lymphoma |
| 257 | Fernando Martin-Moro | Zanubrutinib in Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL): Efficacy and Safety of 101 Spanish Patients Treated in the Real-World on Behalf of GELTAMO | Marginal zone and lymphoplasmacytic lymphoma |
| 258 | Pier Luigi Zinzani | A Meta-Analysis Investigating Response Rates of Continuous BTKi Monotherapies in the Treatment of B-Cell Lymphomas | Marginal zone and lymphoplasmacytic lymphoma |
| 259 | Anastasios Stathis | IELSG49: A Phase II trial of acalabrutinib in combination with tafasitamab in patients with previously treated marginal zone lymphomas | Marginal zone and lymphoplasmacytic lymphoma |
| 260 | Izidore S Lossos | Updated analysis of a phase 2 multicenter study of the loncastuximab in relapsed/refractory marginal zone lymphoma demonstrates high rate of complete responses | Marginal zone and lymphoplasmacytic lymphoma |
| 261 | Eva Kimby | Survival is affected by comorbidity, age and sex - an observational study on 2988 Waldenstrom's macroglobulinemia patients in the Swedish Lymphoma Registry | Marginal zone and lymphoplasmacytic lymphoma |
| 262 | Luca Arcaini | Free Light Chain (FLC) Ratio is an Independent Prognostic Risk Factor for Progression to Symptomatic Waldenstrom’s Macroglobulinemia | Marginal zone and lymphoplasmacytic lymphoma |
| 263 | Karan L Chohan | Long-term outcomes in Waldenström macroglobulinemia (WM) patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapy | Marginal zone and lymphoplasmacytic lymphoma |
| 264 | Morgane Brocard | CD3xCD20 bispecific antibodies in transformed Waldenström macroglobulinemia/lymphoplasmacytic lymphoma | Marginal zone and lymphoplasmacytic lymphoma |
Mantle Cell Lymphoma
| 265 | Simone Ragaini | Impact of IGHV Repertoire after Ibrutinib-Containing Regimens in Younger untreated MCL Patients: An Analysis of the TRIANGLE Data Embedded in the MULTIPLY Project | Mantle Cell Lymphoma |
| 266 | Morgane Cheminant | Integrative Analysis and identification of a predictive Epigenetic Signature in High-risk Mantle Cell Lymphoma: a LYSA study. | Mantle Cell Lymphoma |
| 267 | Katja Gutmair | Evaluation of established prognostic markers in younger mantle cell lymphoma patients under ibrutinib containing regimens - An Analysis Embedded in the MULTIPLY Project | Mantle Cell Lymphoma |
| 268 | Alok Deshane | The Effect of TP53 Mutations on the Local Response of Mantle Cell Lymphoma (MCL) to Radiation Therapy (RT) | Mantle Cell Lymphoma |
| 269 | Morgane Cheminant | Real-world Treatment Patterns and Outcomes Among Patients With Treatment-Naive Mantle Cell Lymphoma in the UK, Sweden, and France | Mantle Cell Lymphoma |
| 270 | Alex Smith | Real-world Treatment Patterns and Outcomes in High-Risk, Treatment-Naive Mantle Cell Lymphoma: A Multinational Analysis From the UK, Sweden, and France | Mantle Cell Lymphoma |
| 271 | Jonathon B. Cohen | Leukemic non-nodal mantle cell lymphoma (nnMCL) is not necessarily equivalent to indolent MCL: A report from the LEO Cohort Study. | Mantle Cell Lymphoma |
| 272 | Preetesh Jain | Acalabrutinib in combination with rituximab is highly effective frontline treatment for older patients with mantle cell lymphoma | Mantle Cell Lymphoma |
| 273 | Enver Aydilek | Real-world outcomes of pirtobrutinib in relapsed/refractory mantle cell lymphoma: a multicenter analysis with a control cohort from the European MCL registry | Mantle Cell Lymphoma |
| 274 | Vanderson Rocha | REAL WORLD ANALYSIS : USE OF BREXUCABTAGENE AUTOLEUCEL FOR RELAPSED REFRACTORY MANTLE CELL LYMPHOMA OF ELDERLY PATIENTS (>70 years old) | Mantle Cell Lymphoma |
| 275 | Linda Simon | Radiotherapy in Patients with Advanced Stage Mantle Cell Lymphoma achieves Durable Local Tumor Control– A SAKK/GLA/EMCL Real-World-Analysis from the EMCL-Registry | Mantle Cell Lymphoma |
| 276 | Alok Deshane | Modern Trends and Outcomes of the Increasing Utilization of Radiation Therapy (RT) in Mantle Cell Lymphoma (MCL) | Mantle Cell Lymphoma |
Aggressive B-cell lymphomas-first line clinical trials
| 277 | Tanja Lazic | Prephase Treatment with Vitamin D Supplementation in Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL): a Randomized Trial by Fondazione Italiana Linfomi (FIL) | Aggressive B-cell lymphomas-first line clinical trials |
| 278 | Heidi Mocikova | Assessing the efficacy and toxicity of CNS prophylaxis in diffuse large B-cell lymphoma (CLSG-CNS-01): a randomized, multicenter, prospective phase 3 trial | Aggressive B-cell lymphomas-first line clinical trials |
| 279 | Ryan C Lynch | Polatuzumab vedotin with dose adjusted etoposide, cyclophosphamide, doxorubicin, and rituximab (PERCH) for upfront treatment of aggressive B-cell non-Hodgkin lymphomas | Aggressive B-cell lymphomas-first line clinical trials |
| 280 | Max S. Topp | Glofitamab combined with R-CHOP or Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): final results from the NP40126 study | Aggressive B-cell lymphomas-first line clinical trials |
| 281 | Lorenzo Falchi | LONG-TERM RESULTS FROM EPCORE NHL-2: FIXED-DURATION EPCORITAMAB + R-CHOP IN PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA WITH HIGH-RISK FEATURES | Aggressive B-cell lymphomas-first line clinical trials |
| 282 | Abraham Avigdor | Durable Efficacy With Fixed-Duration Epcoritamab + Polatuzumab, Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) For 1L DLBCL (EPCORE NHL-5) | Aggressive B-cell lymphomas-first line clinical trials |
| 283 | Evgenii Shumilov | A Ibrutinib and Standard Immunochemotherapy (R-CHOEP) In Younger, High-Risk Patients with DLBCL: a prospective, phase II study of German Lymphoma Alliance (GLA) | Aggressive B-cell lymphomas-first line clinical trials |
| 284 | Zhiming Li | Novel ZCR (Zanubrutinib, Chidamide, Rituximab) ± CHOP Regimen Demonstrates Promising Efficacy in Frontline Treatment of Double-Expressor Diffuse Large B-Cell Lymphoma | Aggressive B-cell lymphomas-first line clinical trials |
| 285 | Yuhong Ren | Efficacy and Safety of Polatuzumab Vedotin, Zanubrutinib and Rituximab (Pola-ZR) in Untreated Elderly and Frail DLBCL Patients: A Prospective Phase 2 Clinical Trial | Aggressive B-cell lymphomas-first line clinical trials |
| 286 | Federico Erbella | The short-term dose-dense CARMEN program is associated with better tolerability and similar efficacy than other intensified regimens in high-grade B-cell lymphomas | Aggressive B-cell lymphomas-first line clinical trials |
| 287 | Piera Angelillo | SHORT-TERM DOSE-DENSE “CARMEN” THERAPY IS BETTER TOLERATED AND EVENLY EFFECTIVE THAN OTHER INTENSIFIED REGIMENS IN HIV- AND HIV+ PATIENTS (PTS) WITH BURKITT LYMHOMA | Aggressive B-cell lymphomas-first line clinical trials |
Aggressive B-cell lymphomas outcomes
| 288 | Yuqin Song | Five-Year Analysis of an Asia Subpopulation with Previously Untreated DLBCL Confirms Pola-R-CHP Benefit on Outcomes: The POLARIX Study | Aggressive B-cell lymphomas outcomes |
| 289 | Swetha Kambhampati Thiruvengadam | Multicenter Real-World Outcomes of Frontline Pola-R-CHP in Treatment Naïve DLBCL | Aggressive B-cell lymphomas outcomes |
| 290 | Nobuhiko Nakamura | Real-world safety and efficacy of Pola-R-CHP in patients with previously untreated DLBCL: analysis of 500 patients in the POLASTAR study | Aggressive B-cell lymphomas outcomes |
| 291 | Patrick Connor Johnson | Match-Adjusted Comparison of Epcoritamab vs Non-Anthracycline Chemoimmunotherapy in Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients With High Cardiovascular Risk | Aggressive B-cell lymphomas outcomes |
| 292 | Juraj Ďuraš | Match-Adjusted Comparative Analysis of the Efficacy of Epcoritamab + R-miniCHOP vs R-miniCHOP in Previously Untreated Diffuse Large B-Cell Lymphoma | Aggressive B-cell lymphomas outcomes |
| 293 | Grzegorz Rymkiewicz | Is MYC-positive high-grade B-cell lymphoma with 11q aberration (HGBCL-11q,MYCR) a new subtype of lymphoma compared to classical MYC-negative HGBCL-11q? | Aggressive B-cell lymphomas outcomes |
| 294 | Pengpeng Xu | Clinical practice pattern and outcomes in DLBCL with distinct genetic subtypes: a large-scale real-world study from China | Aggressive B-cell lymphomas outcomes |
| 295 | Paolo F. Caimi | Early mortality DLBCL prediction with an enhanced R-IPI (eR-IPI) score developed using an ensemble machine learning model. | Aggressive B-cell lymphomas outcomes |
| 296 | Allison Barraclough | Limited stage diffuse large B cell lymphoma in the modern era: Real-world outcomes in an international study of over one thousand patients. | Aggressive B-cell lymphomas outcomes |
| 297 | Andrew Challenger | Causes of excess non-lymphoma death in 60,000 patients with DLBCL diagnosed in England, 1997-2020: An observational cohort study with up to 25 years follow-up | Aggressive B-cell lymphomas outcomes |
| 298 | Joonas Benjamin Kuitunen | The impact of socioeconomic Status on survival of patients with large B-cell lymphoma in Finland, a population-based analysis | Aggressive B-cell lymphomas outcomes |
| 299 | Milla Kuusisto-Jauhiainen | Low socioeconomic status is associated with an inferior prognosis in diffuse large B-cell lymphoma patients despite the age | Aggressive B-cell lymphomas outcomes |
| 300 | Guilherme Duffles | Diffuse Large B-Cell Lymphoma in Brazil: A Comprehensive Analysis of Sociodemographic Patterns | Aggressive B-cell lymphomas outcomes |
| 301 | Hua-Jay J Cherng | Socioeconomic disparities, disease burden and treatment intensity in newly diagnosed diffuse large B-cell lymphoma treated at an urban academic cancer center | Aggressive B-cell lymphomas outcomes |
| 302 | Jelena Jeličić | Predicting outcomes in diffuse large B-cell lymphoma patients eligible for front-line trials using Harkins' enhanced eligibility criteria | Aggressive B-cell lymphomas outcomes |
| 303 | Lucie Oberic | FERTILE: a long-term analysis of fertility among women treated with R-ACVBP/R-CHOP for diffuse large B-cell lymphoma, a retrospective, pooled study of LYSA trials | Aggressive B-cell lymphomas outcomes |
| 304 | Fabian Müller | Imprint of cancer-induced immune scar remains for years and impairs adaptive immunity of NHL survivors | Aggressive B-cell lymphomas outcomes |
| 305 | Silvia Ferrari | RADIATION THERAPY ON SINGLE RESIDUAL PET POSITIVE LESIONS AFTER FRONTLINE CHEMIOIMMUNOTHERAPY IN DIFFUSE LARGE B CELL LYMPHOMA: A SINGLE CENTER RETROSPECTIVE ANALYSIS | Aggressive B-cell lymphomas outcomes |
| 306 | Pau Abrisqueta | Central Nervous System Relapse in High-Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements: A Multicenter Study from the Spanish Group GELTAMO | Aggressive B-cell lymphomas outcomes |
| 307 | Ayo S Falade | Impact of Cell of Origin, Gene Rearrangements, Frontline Treatment on incidence of Central Nervous System (CNS) Lymphoma Relapse in Newly Diagnosed Large B-Cell Lymphoma | Aggressive B-cell lymphomas outcomes |
| 308 | Inna Y Gong | Defining primary refractory disease in large B cell lymphoma and its association with outcomes: a secondary analysis of the LY.12 clinical trial | Aggressive B-cell lymphomas outcomes |
| 309 | Massimiliano Marinoni | Impact of Age on Treatment Decisions and Outcomes in Relapsed/Refractory Large B-Cell Lymphoma | Aggressive B-cell lymphomas outcomes |
| 310 | Mirko Farina | A Multi-center Real-life analysis on patients with Large B-cell Lymphoma after failure of CAR-T cells therapy. | Aggressive B-cell lymphomas outcomes |
| 311 | Inna Y Gong | Outcomes of Patients with Primary Refractory and Early Relapsing Large B cell Lymphoma are Inferior in the CD19 CAR T cell therapy era | Aggressive B-cell lymphomas outcomes |
| 312 | Gloria Iacoboni | Comparison of infectious complications in patients with relapsed/refractory non-Hodgkin lymphoma receiving CAR T cells vs. Bispecific Antibodies. | Aggressive B-cell lymphomas outcomes |
| 313 | Chathuri Abeyakoon | Double Refractory Status Confirms Inferior Survival in Large B-cell Lymphoma Eligible for Third-line CD19 Chimeric Antigen T-cell Therapy | Aggressive B-cell lymphomas outcomes |
| 314 | Annalisa Chiappella | Isolated Central Nervous System (CNS) relapse after CAR-T cell infusion in large B-cell lymphomas (LBCL): an analysis from the Italian CART-SIE Study | Aggressive B-cell lymphomas outcomes |
| 315 | Fernando Martin-Moro | Prognostic Impact of Extranodal Infiltration Based on Anatomic Locations at Plasmablastic Lymphoma Diagnosis in a Multicentric Spanish Series (GELTAMO) | Aggressive B-cell lymphomas outcomes |
Relapsed/refractory aggressive B-cell lymphomas: clinical trials
| 316 | Christopher Melani | Multi-targeted therapy with ViPOR-P in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL): Updated Analysis of Efficacy and Minimal Residual Disease (MRD) | Relapsed/refractory aggressive B-cell lymphomas: clinical trials |
| 317 | Wei Xu | Molecular Subtype-Guided R-MINE+X Regimen in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Single-arm, Open-label, Multicenter Phase II Study | Relapsed/refractory aggressive B-cell lymphomas: clinical trials |
| 318 | Lalita Norasetthada | Phase 2/3 waveLINE-003 Study: Zilovertamab Vedotin Plus Standard of Care in Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) | Relapsed/refractory aggressive B-cell lymphomas: clinical trials |
| 319 | Won Seog Kim | Anbalcabtagene autoleucel (PD-1 and TIGIT knockdown CD19 CAR-T) for relapsed/refractory large B-cell lymphoma (CRC01-01) | Relapsed/refractory aggressive B-cell lymphomas: clinical trials |
| 320 | Chan Y Cheah | Sustained remission with epcoritamab in relapsed/refractory large B-cell lymphoma (LBCL): EPCORE NHL-1 3-y results and analyses in patients with complete response at 2 y | Relapsed/refractory aggressive B-cell lymphomas: clinical trials |
| 321 | Ja Min Byun | Glofitamab, Poseltinib and Lenalidomide (GPL) for patients with relapsed/refractory diffuse large B cell lymphoma | Relapsed/refractory aggressive B-cell lymphomas: clinical trials |
| 322 | Sven de Vos | Epcoritamab + R-ICE in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) eligible for autologous stem cell transplantation (ASCT): EPCORE NHL-2 | Relapsed/refractory aggressive B-cell lymphomas: clinical trials |
Relapsed/refractory aggressive B-cell lymphomas-real world
| 323 | J. Erika Haydu | A prospective analysis of the safety and efficacy of prophylactic dexamethasone for glofitamab administration in relapsed/refractory large B-cell lymphoma | Relapsed/refractory aggressive B-cell lymphomas-real world |
| 324 | Yucai Wang | Rapid Ramp-up Dosing of Bi-specific Antibodies (BsAb) in Relapsed or Refractory (R/R) Large B-cell Lymphoma (LBCL) | Relapsed/refractory aggressive B-cell lymphomas-real world |
| 325 | Vardhaman Patel | Match-Adjusted Comparative Analysis of Epcoritamab + R-DHAX/C or R-ICE vs R-DHAX/C or R-ICE in 2L+ Transplant-Eligible Patients With Diffuse Large B-Cell Lymphoma | Relapsed/refractory aggressive B-cell lymphomas-real world |
| 326 | Wendy Osborne | Glofitamab and Epcoritamab for Large B Cell Lymphoma in 319 Real World Patients: A Retrospective U.K. Analysis of Efficacy, Tolerability and Practical Implications | Relapsed/refractory aggressive B-cell lymphomas-real world |
| 327 | Evgenii Shumilov | Long-term outcome of patients with relapsed/refractory large B-cell lymphoma achieving CR using bispecific antibodies | Relapsed/refractory aggressive B-cell lymphomas-real world |
| 328 | Inna Y Gong | Intention-to-treatment analysis of third line CAR-T for relapse/refractory large B cell lymphoma | Relapsed/refractory aggressive B-cell lymphomas-real world |
CNS Lymphomas
| 329 | Mats Hellström | Circulating protein biomarkers can aid differential diagnosis of primary CNS lymphomas and gliomas | CNS Lymphomas |
| 330 | Elisa Aquilanti | Identification of genomic predictors of survival in primary central nervous system lymphomas. | CNS Lymphomas |
| 331 | Indrani Karpha | Incidence and survival of primary CNS lymphoma: An England-wide cohort study from the UNCOVER Study Group | CNS Lymphomas |
| 332 | li Zou | A multi-center prospective phase II clinical trial of the MEDZ-R regimen for the treatment of newly diagnosed primary central nervous system lymphoma | CNS Lymphomas |
| 333 | Wenrong Huang | Rituximab, high-dose methotrexate plus orelabrutinib as induction therapy in newly diagnosed primary central nervous system lymphoma | CNS Lymphomas |
| 334 | Xudong Zhang | A Phase I/II Study of Orelabrutinib Combined with Anti-PD-1 Antibody and Fotemustine for Patients with Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL) | CNS Lymphomas |
| 335 | Jeong-Ok Lee | The impact of consolidation treatment after R-MVP induction chemotherapy in patients with primary diffuse large B-cell lymphoma of the CNS | CNS Lymphomas |
| 336 | Sylvain CHOQUET | CAR T-cell therapy is highly effective in vitreoretinal lymphomas. A LOC network study | CNS Lymphomas |
| 337 | Igor Age Kos | Allogeneic Hematopoietic Stem Cell Transplantation for Primary Central Nervous System Lymphoma: An Analysis from the EBMT Lymphoma Working Party | CNS Lymphomas |
| 338 | Andrés J. M. Ferreri | THREE-HOUR INFUSION OF METHOTREXATE AT 3 g/m2 SIGNIFICANTLY REDUCES CNS RELAPSES AND IMPROVES SURVIVAL IN PATIENTS WITH LARGE B-CELL LYMPHOMAS AND INCREASED CNS RISK | CNS Lymphomas |
| 339 | Diva Baggio | Outcomes in an international multicentre study of 600 patients with CNS relapse of large B cell lymphoma: Compartment of relapse is prognostic | CNS Lymphomas |
| 340 | Nikita K Dave | Prolonged Methotrexate, Temozolomide and Rituximab in Secondary Central Nervous System Lymphoma | CNS Lymphomas |
| 341 | David Alonso Castronuño | IBRUTINIB FOR THE TREATMENT OF RELAPSED/REFRACTORY PRIMARY OR SECONDARY CENTRAL NERVOUS SYSTEM LARGE B-CELL LYMPHOMAS: EXPERIENCE FROM THE GELTAMO GROUP | CNS Lymphomas |
| 342 | Piera Angelillo | Anti-CD19 chimeric antigen receptor T-cells therapy (CAR-T) is effective in secondary CNS lymphoma (SCNSL) refractory to high-dose methotrexate (HDMTX)-based chemotherapy | CNS Lymphomas |
| 343 | Caron Jacobson | A Pilot Study of Axicabtagene Ciloleucel (axi-cel) for the Treatment of Relapsed/Refractory Primary and Secondary Central Nervous System Lymphoma (CNSL) | CNS Lymphomas |
Primary mediastinal lymphoma
| 344 | TP Vassilakopoulos | RITUXIMAB-DOSE-ADJUSTED EPOCH (R-da-EPOCH) VERSUS RITUXIMAB-CHOP (R-CHOP) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL) | Primary mediastinal lymphoma |
| 345 | Almudena Cabero Martínez | Primary mediastinal large B-cell lymphoma (PMBCL): a multicentric observational study of Spanish lymphoma group GELTAMO. | Primary mediastinal lymphoma |
| 346 | TP Vassilakopoulos | RITUXIMAB-DOSE-ADJUSTED EPOCH (R-da-EPOCH) VERSUS RITUXIMAB-CHOP (R-CHOP) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL) | Primary mediastinal lymphoma |
| 347 | Wen Shu juan | Anti-PD-1 antibody (Tislelizumab) combined with R-CHOP for the treatment of previously untreated primary mediastinal B-cell lymphoma: A prospective phase II study | Primary mediastinal lymphoma |
| 348 | Vittorio Stefoni | Long-term efficacy of immune checkpoint inhibitors for relapsed/refractory primary mediastinal B-cell lymphoma: a retrospective, monocentric study from Bologna, Italy. | Primary mediastinal lymphoma |
| 349 | Alessandro Broccoli | Pembrolizumab or nivolumab combined with brentuximab-vedotin in patients with relapsed/refractory primary mediastinal B-cell lymphoma: an Italian real-life study | Primary mediastinal lymphoma |
| 350 | Anna Guidetti | Patients with relapsed/refractory PMBCL have better survival when the salvage strategy includes CAR T-cells: an analysis of the REPRIME-FIL and the CART-SIE studies | Primary mediastinal lymphoma |
| 351 | John Kuruvilla | Final Safety Analysis in Participants With Hematologic Malignancies Who Received Allogeneic Stem Cell Transplant After Pembrolizumab Therapy | Primary mediastinal lymphoma |
Hodgkin Lymphoma
| 352 | Paul G. Rubinstein | 5-year Update on Frontline Brentuximab Vedotin with AVD for Stage II-IV HIV-associated Classical Hodgkin Lymphoma (AMC-085) | Hodgkin Lymphoma |
| 353 | Astrid Pavlovsky | PET-Adapted Therapy After Three Cycles of ABVD for All Stages of Hodgkin Lymphoma: Long-Term Follow-Up of the GATLA LH-05 Trial | Hodgkin Lymphoma |
| 354 | Alexa Molinari | A matching-adjusted indirect treatment comparison (MAIC) of BrECADD vs N+AVD in populations with advanced Hodgkin lymphoma (aHL) treated in the Front-Line (FL) Setting | Hodgkin Lymphoma |
| 355 | Elżbieta Wojciechowska-Lampka | Efficacy and Safety of the EVA Chemotherapy Regimen in Pregnant Patients with Hodgkin’s Lymphoma: A Long-Term Outcome Analysis | Hodgkin Lymphoma |
| 356 | Justin Ferdinandus | Metabolic Tumor Volume in Older Patients with Advanced-Stage Classic Hodgkin Lymphoma: Results from the GHSG HD21 Trial | Hodgkin Lymphoma |
| 357 | Jan Maciej Zaucha | A short (x3) nivolumab before BGD chemotherapy improves the remission rate in relapsed/refractory Hodgkin Lymphoma: N-BURGUND trial of the Polish Lymphoma Research Group. | Hodgkin Lymphoma |
| 358 | Hishan Tharmaseelan | PD-1-based Salvage Therapy for Relapsed and Refractory Hodgkin Lymphoma: A Multicenter Real-World Analysis | Hodgkin Lymphoma |
| 359 | Wojciech Jurczak | Updated Results From KEYNOTE-B68: Pembrolizumab Every 6 Weeks in Participants with Relapsed or Refractory Classic Hodgkin Lymphoma or Primary Mediastinal B-cell Lymphoma | Hodgkin Lymphoma |
| 360 | Claudia Giordano | Bendamustine supercharge plus brentuximab vedotin as early salvage following failure of 2 ABVD cycles in HL: long-term results of a retrospective multicenter study | Hodgkin Lymphoma |
| 361 | Krimo Bouabdallah | Real-world outcomes of patient with relapsed or refractory Hodgkin lymphoma treated with Brentuximab-Vedotin in association with Bendamustine: the French LYSA experience | Hodgkin Lymphoma |
| 362 | Robin NOEL | Brentuximab Vedotin-ICE as salvage treatment prior to stem cell transplant in Refractory and Relapsed Hodgkin Lymphoma Patients. A Multicenter Real-World Experience |
Hodgkin Lymphoma |
| 363 | Lorena Fiad | Real-World Evidence of Brentuximab Vedotin Consolidation After Autologous Transplant in Relapsed/Refractory Hodgkin Lymphoma (rrHL): 2-Year Follow-Up from the GATLA Study | Hodgkin Lymphoma |
| 364 | Sabrina Pelliccia | The role of stem cell transplantation in patients with R/R classical Hodgkin lymphoma treated with checkpoint inhibitors: Italian multicenter experience | Hodgkin Lymphoma |
| 365 | Aisling Barrett | Association between anthracycline use and clinical outcomes in nearly 2,000 English patients aged 60-79 diagnosed with classical Hodgkin lymphoma between 2012 and 2020 | Hodgkin Lymphoma |
| 366 | Peiqi Zhao | Evolving Treatment Landscape and Outcomes in Elderly Hodgkin Lymphoma: A 15-Year Multicenter Retrospective Analysis from China Highlighting the Impact of Novel Therapies | Hodgkin Lymphoma |
| 367 | Eva Domingo Domenech | AGE, FRAILTY, COMORBIDITIES AND FIRST-LINE TREATMENT IMPACT IN SURVIVAL OF ELDERLY HODGKIN LYMPHOMA PATIENTS: RETROSPECTIVE STUDY FROM THE SPANISH GELTAMO GROUP. | Hodgkin Lymphoma |
| 368 | Kara M. Kelly | The Association of Social Disadvantage with Outcomes in Patients with Advanced-Stage, Classic Hodgkin Lymphoma (cHL) Enrolled in the Phase 3 Intergroup Trial S1826 | Hodgkin Lymphoma |
| 369 | Ilaria Del Giudice | Predicting Thrombotic Risk In Patients With Classical Hodgkin Lymphoma: Thro-HL Multicentre Study | Hodgkin Lymphoma |
| 370 | Beatrice Fregonese | National Social Media Survey for Treatment Decision Making, Financial Toxicity, and Quality of Life in Adolescent and Young Adult Patients with Hodgkin Lymphoma | Hodgkin Lymphoma |
| 371 | Herve Ghesquieres | Synthetic control arm from clinical trial and real-world cohorts from LYSA group for untreated older classical Hodgkin lymphoma for innovative clinical trial designs | Hodgkin Lymphoma |
Pediatric Lymphomas
| 372 | Diana Petcu | Decoding the CD4+T cell- Hodgkin Reed-Sternberg cell crosstalk: how to cut the Achilles' heel of pediatric Hodgkin lymphoma? | Pediatric lymphomas |
| 373 | Sarah Milgrom | Prognostic value of 18F-FDG PET/CT volumetric parameters in childhood, adolescent, and young adult Hodgkin lymphoma: a systematic review from the SEARCH group. | Pediatric lymphomas |
| 374 | Nawar Dakhallah | Imaging Pitfalls in Pediatric, Adolescent, and Young Adult Hodgkin Lymphoma: A SEARCH for CAYAHL Initiative to Bridge Multidisciplinary Patient Care | Pediatric lymphomas |
| 375 | Jia Zhu | Real world study of efficacy and safety of PD-1 antibody monotherapy and combination therapy in pediatric lymphoma patients in South China | Pediatric lymphomas |
| 376 | Luciana Vinti | CD20-negative relapsed/refractory mature B-cell non-Hodgkin lymphoma (B-NHLs) and mature B-cell leukemia in children, adolescent andh young adults: a retrospective review | Pediatric lymphomas |
| 377 | Linnan Wu | Late Complications and Quality of Life in Long-Term Survivors of Childhood, Adolescent, and Young Adult Hodgkin Lymphoma | Pediatric lymphomas |
PTLD
| 378 | Ana Jiménez-Ubieto | Exploring a New Prognostic Index in 341 Post-Transplant Lymphoproliferative Disorders in the “Rituximab Era”: A Retrospective Study from Spanish Lymphoma Group GELTAMO | PTLD |
| 379 | Benjamin Delarras | Causes of death in post-transplant lymphoproliferative disorders: an analysis of the French K-VIROGREF registry | PTLD |
| 380 | Ana Jiménez-Ubieto | First-line Therapy with Rituximab vs. Rituximab-CHOP in Post-Transplant Monomorphic Diffuse Large B-Cell Lymphoma: A Large Series from Spanish Group of Lymphoma (GELTAMO) | PTLD |
| 381 | Emilie Corvilain | CD19 CAR-T cell therapy in relapsed/refractory solid organ transplant-related lymphoproliferation: A LYSA analysis of the French cohort DESCAR-T | PTLD |
NK/T-cell Lymphomas
| 382 | Francine Marie Ms Foss | Gene copy number alterations identify subset of Sezary syndrome patients with worse survival outcomes. | NK/T-cell Lymphomas |
| 383 | Michelle Afkhami | Next-Generation Sequencing Reveals T Cell Receptor Beta and Gamma Clonotypes Associated with Aggressive Subtypes of Mycosis Fungoides/Sezary Syndrome and Poor Prognosis | NK/T-cell Lymphomas |
| 384 | DACHUAN HUANG | Prognostic and Functional Impact of EGF-JAK/STAT Pathway Mutations in Angioimmunoblastic T-cell Lymphoma (AITL) | NK/T-cell Lymphomas |
| 385 | Yi Zhong | The prognostic role of whole blood Epstein‑Barr virus DNA load in angioimmunoblastic T-cell lymphoma | NK/T-cell Lymphomas |
| 386 | Thais Fischer | Number of extranodal sites in PTCL as prognostic marker in real-world setting. An analysis of 645 cases enrolled in the T-Cell Project 2. | NK/T-cell Lymphomas |
| 387 | Christopher Fox | Survival outcomes for patients with extra-nodal NK/T lymphoma; data from 110 patients prospectively registered in the International T-Cell Project 2 | NK/T-cell Lymphomas |
| 388 | Stefano Luminari | Clinical Outcomes and Prognostic Factors in Nodal Aggressive T-Cell Lymphomas: Insights from 655 cases registered in the T-Cell Project 2.0 | NK/T-cell Lymphomas |
| 389 | Carlos S Chiattone | The outcome of Adult T-Cell Leukemia/Lymphoma in Real world setting: Insights from the T-Cell Project 2.0 | NK/T-cell Lymphomas |
| 390 | Chathuri Abeyakoon | End-of-treatment PET/CT Complete Remission is Highly Prognostic in Nodal Peripheral T-cell Lymphoma: An Australasian-Canadian Collaborative Study | NK/T-cell Lymphomas |
| 391 | Chong Wei | A phase II study of azacitidine and chidamide plus CHOP versus CHOP in previously untreated patients with peripheral T-cell lymphoma | NK/T-cell Lymphomas |
| 392 | Liu Wei | Chidamide in combination with azacitidine, mitoxantrone liposomes, and prednisone (CAMP regimen) for treatment-naïve TFH-derived peripheral T-cell lymphoma | NK/T-cell Lymphomas |
| 393 | David Sibon | BV-CHP followed by autologous stem-cell transplantation in newly diagnosed Enteropathy-Associated T-cell lymphoma: Final results of the EATL-001 phase 2 study | NK/T-cell Lymphomas |
| 394 | Amira Marouf | Ruxolitinib targets STAT1-STAT3 cooperatively in large granular lymphocytic leukemia. | NK/T-cell Lymphomas |
| 395 | Kaitlyn Lapen | Total Skin Electron Beam Therapy (TSEBT) for Mycosis Fungoides in the Modern Era of TSEBT Dose Reduction and Diversified Systemic Therapy | NK/T-cell Lymphomas |
| 396 | Christiane Querfeld | Ongoing Phase 2, Open-Label, Multicenter, Single-Arm Study Assessing an Every-4-Week Dosing Schedule of Mogamulizumab in Cutaneous T-Cell Lymphoma: Preliminary Results | NK/T-cell Lymphomas |
| 397 | Andres McAllister | Robust Single Agent Activity of BI-1808, a Tumor Necrosis Factor Receptor 2 (TNFR2) Blocker/Depleter, in T Cell Lymphoma (TCL) Patients | NK/T-cell Lymphomas |
| 398 | Youn H Kim | Lacutamab in patients with relapsed and/or refractory mycosis fungoides: long term follow-up and translational data from the TELLOMAK phase 2 trial | NK/T-cell Lymphomas |
| 399 | Christiane Querfeld | Durvalumab & Lenalidomide Shows Superior Efficacy Over Single-Agent Durvalumab in Refractory/Advanced Cutaneous T Cell Lymphoma: Results from a Randomized Phase 2 Trial | NK/T-cell Lymphomas |
| 400 | Rong Tao | A Multi-center, Prospective Study of the Efficacy and Safety of PD-1 Antibody Sintilimab in Combination With Pegaspargase and Anlotinib in Stage IV NKTCL Patients | NK/T-cell Lymphomas |
| 401 | Won Seog Kim | Phase II study of concurrent tislelizimab and radiotherapy for treatment-naïve, newly diagnosed low-risk Extranodal NK/T-cell lymphoma, nasal type | NK/T-cell Lymphomas |
| 402 | Nazarii Shokun | Relapsed/refractory Peripheral T-Cell Lymphomas: Report on 641 patients from the T-Cell Project 2.0. | NK/T-cell Lymphomas |
Multiple Myeloma
| 403 | Yuping Zhong | A single-arm, multi-center, observational study of Selinexor combined bortezomib, lenalidomide, and dexamethasone in high-risk newly diagnosed multiple myeloma(NDMM) | Multiple Myeloma |
| 404 | Gaurav Chatterjee | Clinical relevance of Peripheral Blood Measurable Residual Disease(PBMRD) assessment in newly diagnosed Multiple Myeloma after Initial Therapy: A prospective study | Multiple Myeloma |
| 405 | Alexandra D Dreyfuss | Trends in the incorporation of radiotherapy in the management of Multiple Myeloma over the past decade: High local control rate and factors associated with its durability | Multiple Myeloma |
| 406 | Chirayu G Patel | Combining Bispecifics and Radiation for Rel/Ref Hematologic Malignancies: Friend or Foe? | Multiple Myeloma |
| 407 | Beatrice Fregonese | Radiation Therapy for Oligo-Relapsed/Progressive Disease Post-Stem Cell Transplant for Multiple Myeloma: Factors Associated with Favorable Outcomes | Multiple Myeloma |
Imaging and radiomics
| 408 | Beatrice Casadei | Integrative Profiling of Gut Microbiome and FDG-PET Parameters as Predictors of CAR T-cell Therapy Outcomes in Relapsed/Refractory Diffuse Large B-cell Lymphomas. | Imaging and radiomics |
| 409 | Cinzia Pellegrini | Early Identification of CAR T-Cell Therapy Non-Responders in Relapsed/Refractory Large B-Cell Lymphoma Using FDG-PET Quantitative Parameters | Imaging and radiomics |
| 410 | Maria C Ferrandez Ferrandez | Evaluation of an artificial intelligence method for lesion segmentation of baseline FDG PET studies of DLBCL patients | Imaging and radiomics |
| 411 | Andrea Gallamini | The search for baseline imaging predictive factors of refractoriness to ABVD in the low and very low risk patients with early stages HL of the RAFTING trial | Imaging and radiomics |
| 412 | Anne Bes | Improving the predictive value of End-of-Treatment PET/CT in diffuse large B-cell lymphoma | Imaging and radiomics |
| 413 | Alexandra D Dreyfuss | Progression patterns by positron emission tomography (PET) for relapsed/refractory Multiple Myeloma (RRMM) after CAR T cell therapy: Potential role for radiotherapy (RT)? | Imaging and radiomics |
| 414 | Lea Mantz | CT-based body composition in patients with follicular lymphoma compared with the general population, and association between body composition and lymphoma outcomes | Imaging and radiomics |
Liquid Biopsy
| 415 | Alessia Bottos | Circulating Tumor DNA (ctDNA) at Screening as a Prognostic Marker in Untreated Follicular Lymphoma from the GALLIUM Trail Using a Next Generation Sequencing (NGS) Assay | Liquid Biopsy |
| 416 | Ana Jiménez Ubieto | Real-life Disease Monitoring in Relapsed/Refractory Follicular Lymphoma Patients Using Liquid Biopsy Ultra-Deep Sequencing | Liquid Biopsy |
| 417 | Andrea Gallamini | TMTV < than 32,5 ml impairs the successful detection of ctDNA in early-stage Hodgin lymphoma patients – the preliminary report from the RAFTING trial | Liquid Biopsy |
| 418 | Ryan C. Lynch | Circulating tumor DNA assessment in patients with early-stage classical Hodgkin lymphoma treated with combination of brentuximab vedotin and nivolumab | Liquid Biopsy |
| 419 | Patrick Gould | Multicenter Real-World Outcomes in Diffuse Large B-Cell Lymphoma Profiled with a Commercially-Available Circulating Tumor DNA Assay | Liquid Biopsy |
| 420 | Irit Avivi | Detection and Monitoring of response to treatment of B Cell Lymphomas By a Simple Epigenetic Blood Test | Liquid Biopsy |
| 421 | Ryan N Rys | ctDNA Dynamics of Refractory Diffuse Large B Cell Lymphoma | Liquid Biopsy |
| 422 | Wei Xu | Molecular features encoded in the dynamic ctDNA monitoring reveal prognostic value, different clinical courses and clone evolution for different genetic subtypes of DLBCL | Liquid Biopsy |
| 423 | Mark R. Dowling | ctDNA-directed intervention with epcoritamab alone or in combination with lenalidomide-rituximab is feasible in the early post-CAR-T population at high risk of relapse | Liquid Biopsy |
| 424 | Stefano Luminari | Longitudinal targeted ctDNA analysis to assess CD20 and BAFF mutations in patients with relapsed/refractory FL or DLBCL progressing on odronextamab in the ELM-2 study | Liquid Biopsy |
| 425 | Emmanuel Bachy | Biomarker analyses of the inflammatory profile and MRD in patients with relapsed/refractory marginal zone lymphoma versus follicular lymphoma treated with odronextamab | Liquid Biopsy |
| 426 | Andrew Steele | EPCORITAMAB+GEMOX LEADS TO HIGH MRD-NEGATIVITY RATES IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL): AN UPDATED LONGITUDINAL MRD ANALYSIS | Liquid Biopsy |
| 427 | Snegha Ananth | Monitoring Ciruclating Tumor DNA Improves Early Relapse Detection After Standard of care 2L+ Axi-cel in LBCL: A Prospective Study | Liquid Biopsy |
Experimental therapeutics
| 428 | Maidel Carpio | The synthetic peptide CIGB-552 induces cell death and enhances ibrutinib efficacy in marginal zone lymphoma (MZL), including drug-resistant models | Experimental therapeutics |
| 429 | Francesca Guidetti | Loss of enhancer-derived lncRNA ZMIZ1-AS1 increases the sensitivity to BCL2-inhibitor venetoclax in MCL in vitro models | Experimental therapeutics |
| 430 | Sean Landrette | ARV-393, a PROTAC BCL6 degrader, combined with biologics or small-molecule inhibitors induces tumor regressions in diffuse large B-cell lymphoma models | Experimental therapeutics |
| 431 | Anand D Jeyasekharan | EZH2 gain-of-function mutations confer everolimus sensitivity in diffuse large B cell lymphoma | Experimental therapeutics |
| 432 | Nicolas Munz | Loss of enhancer-derived lncRNA U47924.31 decreases R-CHOP sensitivity and is associated with inferior outcome in diffuse large B cell lymphoma (DLBCL) patients | Experimental therapeutics |
| 433 | Vincenzo Maria Perriello | DEVELOPMENT OF HIGH-AFFINITY CD79B CAR-T CELLS TO OVERCOME ANTIGEN ESCAPE OF RELAPSED/REFRACTORY B-NON HODGKIN LYMPHOMAS AND MULTIPLE MYELOMA | Experimental therapeutics |
| 434 | Samy Jambon | P-CD19CD20-ALLO1: A TSCM-Predominant Allogeneic CAR-T Therapy Targeting CD19 and CD20 for B-cell Malignancies Demonstrates Advantages Beyond Preventing Antigen Escape | Experimental therapeutics |
| 435 | Weiyun Ai | Integrated Gene Expression and Pathway Enrichment Analyses Following CDK9 Inhibition in Cutaneous T-cell Lymphoma Patient-Derived Xenograft (PDX) Models | Experimental therapeutics |
Novel compounds
| 436 | Pier Luigi Zinzani | Updated Efficacy/Safety of Bruton Tyrosine Kinase (BTK) Degrader BGB-16673 in Patients with Relapsed/Refractory (R/R) Indolent NHL: Ongoing Phase 1 CaDAnCe-101 Results | Novel compounds |
| 437 | David Lewis | Bexobrutideg (NX-5948), a novel BTK degrader, shows high clinical activity and tolerable safety in an ongoing Phase 1a/b study in Waldenström macroglobulinemia | Novel compounds |
| 438 | Yucai Wang | Orelabrutinib for the treatment of relapsed/refractory mantle cell lymphoma: efficacy and safety results from a global phase 1/2 study | Novel compounds |
| 439 | Huilai Zhang | Analysis of a Phase 1 Study of Zanubrutinib (Zanu) + Lenalidomide (Len) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) | Novel compounds |
| 440 | Michael J Dickinson | GoldiLox: First Experience of Two Dosing Strategies of Pirtobrutinib and Glofitamab for Mantle Cell Lymphoma Previously Treated with Covalent BTK Inhibitors | Novel compounds |
| 441 | Guilherme Perini | Golcadomide, a Cereblon E3 Ligase Modulator (CELMoD™) Agent ± Rituximab, in Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL): Updated Phase 1/2 Results | Novel compounds |
| 442 | Raphael Steiner | Novel Devimistat Results in Complete Remissions in Heavily Pre-Treated Burkitt Lymphoma | Novel compounds |
| 443 | Wojciech Jurczak | A Phase 1 Study of PRT2527, a Selective CDK9 Inhibitor, as Monotherapy and in Combination With Zanubrutinib in Relapsed/Refractory Lymphoid Malignancies: Updated Analysis | Novel compounds |
| 444 | Stephen Spurgeon | A Phase 1 study of SGR-1505, an oral, potent MALT1 inhibitor for R/R B-cell malignancies, including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) | Novel compounds |
| 445 | Swaminathan Iyer | ELA026, a monoclonal antibody targeting SIRP-expressing myeloid cells and T lymphocytes, demonstrates broad anti-tumor activity in patients with lymphoma | Novel compounds |
CAR T-cell therapy
| 446 | Estelle BOURBON | Impact of Response to Holding/Bridging Therapy in Second-line DLBCL Patients Treated with Axicabtagene ciloleucel: a LYSA Study from the French DESCAR-T Registry | CAR T-cell therapy |
| 447 | Giulia Gabrielli | POLATUZUMAB-CONTAINING REGIMENS AS BRIDGE TO CAR-T: INSIGHTS FROM THE ITALIAN CAR T-SIE STUDY | CAR T-cell therapy |
| 448 | Hanna Katharina Zieger | Bispecific antibodies as holding or bridging therapy before CAR-T in large B-cell lymphoma | CAR T-cell therapy |
| 449 | Marie A-C. Neumann | Bridging to CAR-T cell therapy in large B-cell lymphoma with either conventional therapy or the CD3xCD20 bispecific antibody glofitamab | CAR T-cell therapy |
| 450 | Chirayu Patel | 5-5-5 ABRT (Adaptive Bridging Radiation Therapy) – Artificial Intelligence Enters the CAR (-T) in Relapsed/Refractory Large B-Cell Lymphoma: Updated Analysis | CAR T-cell therapy |
| 451 | Roshal R. Patel | MYC Alterations Confer Worse Local Control In Patients Undergoing Bridging Radiotherapy Prior to CAR-T | CAR T-cell therapy |
| 452 | Roshal R Patel | Bridging Radiotherapy Does Not Increase Risk of CAR T-cell Associated Toxicity | CAR T-cell therapy |
| 453 | Kathryn Tringale | Efficacy and Toxicity of Radiation Therapy Prior to Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma | CAR T-cell therapy |
| 454 | Inna Gong | Association of bridging therapy with response and outcomes in patients with relapsed/refractory large B cell lymphoma receiving third line CAR-T | CAR T-cell therapy |
| 455 | Alaa Ali | Bendamustine as Lymphodepleting Chemotherapy (LDC) Prior to Axicabtagene Ciloleucel (Axi-Cel) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL) | CAR T-cell therapy |
| 456 | Kunhwa Kim | Identification of an Optimal Absolute Lymphocyte Count Before Leukapheresis in Large B-cell Lymphoma Patients Treated with CART | CAR T-cell therapy |
| 457 | Teny M John | Breath Biomarkers for Prediction of Cytokine Release Syndrome in Patients Receiving Chimeric Antigen Receptor T-cell Therapy | CAR T-cell therapy |
| 458 | Manali Kamdar | Optimizing post–chimeric antigen receptor T cell monitoring: evidence across lisocabtagene maraleucel pivotal clinical trials and real-world experience | CAR T-cell therapy |
| 459 | Andrea Kuhnl | Outcomes of second-line axicabtagene ciloleucel for large B-cell lymphoma in the UK | CAR T-cell therapy |
| 460 | Louise Olsson Werne | Circulating CAR T-cells after treatment with axicabtagene ciloleucel in patients with R/R aggressive B-cell lymphomas and its association to treatment outcome | CAR T-cell therapy |
| 461 | Nicole Fabbri | Outcomes of CAR T-Cell Therapy in Transformed Indolent Non-Hodgkin Lymphomas and de novo DLBCL: a comparative analysis from the Italian CAR T-SIE study | CAR T-cell therapy |
| 462 | Vanderson Rocha | Outcomes After CAR-T cell Therapy (Tisagenlecleucel or Axicabtagene ciloleucel) in patients older than 70 years with Diffuse Large B Cell Lymphoma | CAR T-cell therapy |
| 463 | Axel André | Anti-CD19 CAR-T Cell Therapy in Relapsed/Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma (THRLBCL): Insights from the French DESCAR-T Registry, a LYSA Study. | CAR T-cell therapy |
New cellular therapies
| 464 | William Wilson | Durable responses and favourable toxicity after fast off-rate CD19 CAR T-cell therapy with obecabtagene autoleucel in adults with relapsed/refractory B-cell malignancies | New cellular therapies |
| 465 | Marie José Kersten | Low Rates of High-Grade Toxicities With GLPG5101, a Fresh, Stem-Like, Early Memory Phenotype Anti-CD19 CAR T-Cell Therapy in Patients With NHL in the ATALANTA-1 Study | New cellular therapies |
| 466 | Ling-Shuang Sheng | CAR-T Therapy with OX40 Signaling Drives Clonal Expansion of CD4+ T Cells and Overcomes Immunosuppressive Microenvironment in B-Cell Lymphoma: A Phase I Trial | New cellular therapies |
| 467 | Matthew Lunning | Safety and Efficacy of FT522, an Off-the-Shelf, iPSC ‑Derived CD19 CAR NK Cell Therapy with Alloimmune defense Receptor (ADR) in Relapsed/Refractory B-Cell Lymphoma | New cellular therapies |
| 468 | R.Alejandro Sica | First-in-human CART cells for Adult T-Cell Leukemia/Lymphoma (ATLL) using CTX130, a CD70-Targeted Allogeneic CRISPR-Cas9-Engineered CART-Cells. COBALT-LYM Study Cohort. | New cellular therapies |